Confo Therapeutics, a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a Phase 2a clinical trial to evaluate ...

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered a collaboration agreement ...

Ghent, Belgium – October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million ...

Eli Lilly will take the baton on developing a peripheral pain candidate from Confo Therapeutics, handing off $40 million upfront and a potential $590 million total down the track if all goes well.

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli ...

Confo Therapeutics’ business development team is on a roll. Weeks after licensing its lead candidate to Eli Lilly, the Belgian biotech has landed a 168 million euro ($182 million) deal with Daiichi ...

The pain drug market has many products, but there’s still a need for pills with better properties, such as avoiding addiction. Eli Lilly sees potential in the non-opioid pain drug research from Confo ...

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH ...

Discovery of highly potent and selective antibody-based GPCR agonists targeting Melanocortin 4 Receptor (MC4R), a key regulator for hunger and satiety, using Confo's proprietary technology platform ...

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable ...

Ghent, Belgium - April 30, 2026 - Confo Therapeutics, a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a ...